AACR 2024 | Serum thymidine kinase 1 as a predicative biomarker in prostate cancer

Teemu Murtola, MD, PhD, University of Tampere, Tampere, Finland, discusses the potential of serum thymidine kinase 1 (TK1) as a predictive marker for castration resistance in metastatic prostate cancer. Patients with metastatic prostate cancer undergoing androgen deprivation therapy (ADT) had their serum STK1 levels measured before and 6 months after starting ADT, and within 6 months before the development of castration resistance. Serum STK1 was found to be correlated to progression in patients 6 months after starting ADT. This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.